Antibody Drug Conjugates: Technologies and Global Markets
Build your market intelligence strategies with our antibody drug conjugates market report insightful analysis and five year CAGRs by segment.
CHAPTER 1: INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2: SUMMARY AND HIGHLIGHTS
CHAPTER 3: MARKET AND TECHNOLOGY BACKGROUND
Definitions
Components of ADCs
How ADCs Work
Historical Perspective
Advantages of ADCs
Approved ADCs
Mylotarg (Gemtuzumab Ozogamicin)
Adcetris (Brentuximab Vedotin)
Kadcyla (Trastuzumab-DM1)
Antibody Drug Conjugation Technologies
Key ADC Targets
CD19
CD20
CD22
CD25
CD30
CD33
CD40
CD56
CD74
CD79a and CD79b
CD138 (Syndecan-1)
CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
EGFR (Epidermal Growth Factor Receptor/ERBB1)
EGP-1 (Epithelial Glycoprotein-1 Antigen)
GPNMB
HER2 (Human Epidermal Growth Factor Receptor)
LIV-1
Mesothelin
Nectin-4
Prostate-Specific Membrane Antigen (PSMA)
SLITRK6
VEGF (Vascular Endothelial Growth Factor)
Types of Monoclonal Antibodies
Types of Payloads (Cytotoxic Agents)
Types of Linkers
Conjugation Methods
Conventional Conjugation Method
Site-Specific Conjugation
CHAPTER 4: MARKET BREAKDOWN BY TECHNOLOGY TYPE
Market for ADCs by Type of Payload
Market Overview
Market Revenues
Market for ADCs by Type of Monoclonal Antibody
Market Overview
Market Revenues
Market for ADCs by Type of Linker
Market Overview
Market Revenues
CHAPTER 5: MARKET BREAKDOWN BY APPLICATION
Global Market for the Application of ADCs in Treating Various Types of Cancers
Market Share
Breast Cancer
Lymphoma
Other Types of Cancer
CHAPTER 6: INDUSTRY STRUCTURE
Market Leaders
Market Share
CHAPTER 7: MARKET BREAKDOWN BY REGION
Market Overview
Market Revenues
Market for ADCs by Target Antigen
Market for CD-30 Targeting ADCs
Market for HER2 Targeting ADCs
Market for Other Antigen Targeting ADCs
CHAPTER 8: PATENT REVIEW/NEW DEVELOPMENTS
Patent Analysis
Patents by Year
Patents by Company
Patents by Country
Patents by Assignee
New Developments
CMC-544
CDX-011
RG7596 (Polatuzumab Vedotin)
RG7593 (Pinatuzumab Vedotin)
PSMA ADC
IMGN853 (Mirvetuximab Soravtansine)
BT-062
Regulatory Issues
Regulatory History of Approved ADCs
Regulatory Exclusivity
Other Regulatory Issues
CHAPTER 9: ANALYSIS OF MARKET OPPORTUNITIES
Key Drivers
Patent Expiration
Targeted Nature of ADCs
Complexity of ADCs
Investor Confidence in Biologics
Increased Research on ADC Development
Other Factors
Key Challenges
Manufacturer Strategies
CHAPTER 10: COMPANY PROFILES
Appendix: Abbreviations
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2: SUMMARY AND HIGHLIGHTS
CHAPTER 3: MARKET AND TECHNOLOGY BACKGROUND
Definitions
Components of ADCs
How ADCs Work
Historical Perspective
Advantages of ADCs
Approved ADCs
Mylotarg (Gemtuzumab Ozogamicin)
Adcetris (Brentuximab Vedotin)
Kadcyla (Trastuzumab-DM1)
Antibody Drug Conjugation Technologies
Key ADC Targets
CD19
CD20
CD22
CD25
CD30
CD33
CD40
CD56
CD74
CD79a and CD79b
CD138 (Syndecan-1)
CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
EGFR (Epidermal Growth Factor Receptor/ERBB1)
EGP-1 (Epithelial Glycoprotein-1 Antigen)
GPNMB
HER2 (Human Epidermal Growth Factor Receptor)
LIV-1
Mesothelin
Nectin-4
Prostate-Specific Membrane Antigen (PSMA)
SLITRK6
VEGF (Vascular Endothelial Growth Factor)
Types of Monoclonal Antibodies
Types of Payloads (Cytotoxic Agents)
Types of Linkers
Conjugation Methods
Conventional Conjugation Method
Site-Specific Conjugation
CHAPTER 4: MARKET BREAKDOWN BY TECHNOLOGY TYPE
Market for ADCs by Type of Payload
Market Overview
Market Revenues
Market for ADCs by Type of Monoclonal Antibody
Market Overview
Market Revenues
Market for ADCs by Type of Linker
Market Overview
Market Revenues
CHAPTER 5: MARKET BREAKDOWN BY APPLICATION
Global Market for the Application of ADCs in Treating Various Types of Cancers
Market Share
Breast Cancer
Lymphoma
Other Types of Cancer
CHAPTER 6: INDUSTRY STRUCTURE
Market Leaders
Market Share
CHAPTER 7: MARKET BREAKDOWN BY REGION
Market Overview
Market Revenues
Market for ADCs by Target Antigen
Market for CD-30 Targeting ADCs
Market for HER2 Targeting ADCs
Market for Other Antigen Targeting ADCs
CHAPTER 8: PATENT REVIEW/NEW DEVELOPMENTS
Patent Analysis
Patents by Year
Patents by Company
Patents by Country
Patents by Assignee
New Developments
CMC-544
CDX-011
RG7596 (Polatuzumab Vedotin)
RG7593 (Pinatuzumab Vedotin)
PSMA ADC
IMGN853 (Mirvetuximab Soravtansine)
BT-062
Regulatory Issues
Regulatory History of Approved ADCs
Regulatory Exclusivity
Other Regulatory Issues
CHAPTER 9: ANALYSIS OF MARKET OPPORTUNITIES
Key Drivers
Patent Expiration
Targeted Nature of ADCs
Complexity of ADCs
Investor Confidence in Biologics
Increased Research on ADC Development
Other Factors
Key Challenges
Manufacturer Strategies
CHAPTER 10: COMPANY PROFILES
Appendix: Abbreviations
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
LIST OF TABLES
Summary Table: Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 1 History of Antibody Drug
Table 2 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
Table 3 Significant Antibody Drug Conjugate Payloads
Table 4 Significant Antibody Drug Conjugate Linkers
Table 5 Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens
Table 6 Antibody Drug Conjugates with Significant Market Potential During the Forecast Period
Table 7 Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021 ($ Millions)
Table 8 Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021 ($ Millions)
Table 9 Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021 ($ Millions)
Table 10 Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021 ($ Millions)
Table 11 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
Table 12 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 13 Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 14 Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 15 Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
Table 16 Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016 (%)
Table 17 Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 18 Significant Early Stage Clinical Trials on Adcetris, 2017
Table 19 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 20 Significant Early Stage Clinical Trials on Kadcyla, 2017
Table 21 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 22 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ MILLIONS)
Table 23 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Table 24 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Table 25 Number of U.S. Patents on ADCs by Assignee’s Country, 2013 Through Feb. 2017
Table 26 U.S. Patent Shares of ADCs by Assignee’s Country, 2013 Through Feb. 2017 (No./%)
Table 27 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
Table 28 Number of Investigational New Drug Applications Filed, 2003-2016
Table 29 ADCs in Research Pipeline as of Feb. 2017
Table 30 Orphan Drug Designations Granted for Adcetris
Table 31 Major Alliances for ADC Development
Table 32 Abbreviations Used in Antibody Drug Conjugates
Summary Table: Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 1 History of Antibody Drug
Table 2 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
Table 3 Significant Antibody Drug Conjugate Payloads
Table 4 Significant Antibody Drug Conjugate Linkers
Table 5 Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens
Table 6 Antibody Drug Conjugates with Significant Market Potential During the Forecast Period
Table 7 Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021 ($ Millions)
Table 8 Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021 ($ Millions)
Table 9 Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021 ($ Millions)
Table 10 Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021 ($ Millions)
Table 11 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
Table 12 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 13 Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 14 Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 15 Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
Table 16 Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016 (%)
Table 17 Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 18 Significant Early Stage Clinical Trials on Adcetris, 2017
Table 19 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 20 Significant Early Stage Clinical Trials on Kadcyla, 2017
Table 21 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
Table 22 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ MILLIONS)
Table 23 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Table 24 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Table 25 Number of U.S. Patents on ADCs by Assignee’s Country, 2013 Through Feb. 2017
Table 26 U.S. Patent Shares of ADCs by Assignee’s Country, 2013 Through Feb. 2017 (No./%)
Table 27 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
Table 28 Number of Investigational New Drug Applications Filed, 2003-2016
Table 29 ADCs in Research Pipeline as of Feb. 2017
Table 30 Orphan Drug Designations Granted for Adcetris
Table 31 Major Alliances for ADC Development
Table 32 Abbreviations Used in Antibody Drug Conjugates
LIST OF FIGURES
Summary Figure: Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 1 Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021 ($ Millions)
Figure 2 Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021 ($ Millions)
Figure 3 Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021 ($ Millions)
Figure 4 Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021 ($ Millions)
Figure 5 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
Figure 6 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 7 Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 8 Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 9 Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 (%)
Figure 10 Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 11 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 12 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 13 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 14 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Figure 15 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Figure 16 Number of U.S. Patents on ADCs by Assignee’s Country, 2013 Through Feb. 2017
Figure 17 U.S. Patent Shares of ADCs by Assignee’s Country, 2013 Through Feb. 2017 (%)
Figure 18 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
Summary Figure: Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 1 Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021 ($ Millions)
Figure 2 Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021 ($ Millions)
Figure 3 Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021 ($ Millions)
Figure 4 Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021 ($ Millions)
Figure 5 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
Figure 6 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 7 Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 8 Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 9 Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 (%)
Figure 10 Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 11 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 12 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 13 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
Figure 14 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Figure 15 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Figure 16 Number of U.S. Patents on ADCs by Assignee’s Country, 2013 Through Feb. 2017
Figure 17 U.S. Patent Shares of ADCs by Assignee’s Country, 2013 Through Feb. 2017 (%)
Figure 18 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
